Review
Published · Updated · 1 min read
Selpercatinib and other perioperative strategies in localized non-small cell lung cancer
What it means for practice
The review emphasizes molecular profiling to guide perioperative strategies in non-small cell lung cancer and highlights the potential of neoadjuvant approaches in selected patients.
Summary
This review addresses advances in perioperative strategies for localized non-small cell lung cancer (NSCLC), focusing on targeted therapies. The supplied abstract summarizes findings on selpercatinib, erlotinib, osimertinib, nivolumab and lorlatinib, with an emphasis on tumor molecular characteristics.
Key findings
- According to the abstract, selpercatinib provided a significant benefit in RET fusion-positive NSCLC in LIBRETTO-432, reducing the risk of recurrence or death by 83%.
- In Alliance A081105, erlotinib improved disease-free survival but not overall survival. Osimertinib remains the standard of care in the review’s account.
- Nivolumab did not demonstrate a benefit in disease-free survival.
- Lorlatinib showed promise as neoadjuvant treatment for ALK-rearranged tumors.
Clinical context and evidence limits
The review emphasizes molecular profiling and the potential of neoadjuvant strategies in selected patients. The abstract provides no sample sizes, comparator groups, follow-up durations, confidence intervals or safety data. It also does not describe the limitations of individual studies, preventing a detailed assessment from this account.
Source
-
CBNPC localisés : de nouvelles avancées pour les stratégies périopératoires.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer